Necessary cookies Always active These cookies are essential for the website to work properly and can't be switched off
The effect of 2.4 mg once-weekly injected semaglutide in patients with HFpEF, obesity and T2D is currently investigated in an ongoing trial STEP-HFpEF DM (Semaglutide Treatment Effect in People with obesity and HFpEF and type 2 diabetes) (64, 65)
Retatrutide a triple agonist of GLP-1, GIP, and glucagon receptors (half-life ~6 days), promoting insulin secretion, hepatic fat oxidation, appetite suppression, and energy expenditure
Its triple agonism allows simultaneous study of combined GLP-1 + GIP + glucagon effects, experimental dissections impossible with mono-agonists or dual agonists
For people aiming for significant weight loss, I doubt they will see the desired outcomes with these over-the-counter supplements, says Dr